Acadia Pharmaceuticals (ACAD +1.3%) says it receiving funding from Fast Forward, LLC, a...

|By:, SA News Editor

Acadia Pharmaceuticals (ACAD +1.3%) says it receiving funding from Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA (MCGAY.PK). The funding will go to support R&D directed at using AC-186, ACAD’s estrogen receptor (ER)-beta agonist, as a new approach to the treatment of multiple sclerosis.